lifestyle.utv.ie

Author: Basilea Pharmaceutica International Ltd, Allschwil

Basilea shareholders approve all proposals of the board of directors at the 2026 annual general meeting

May 3, 2026
Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420

May 2, 2026
Basilea announces start of first‑in‑human study of novel antibiotic BAL2420

April 30, 2026
Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam

February 25, 2026
Basilea reports strong 2025 full-year results, surpassing revenue and operating profit guidance

February 17, 2026
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

February 10, 2026